Charles River Laboratories International Inc（CRL）资讯与事件CRLCharles River Laboratories International Inc

Charles River Laboratories Partners with Magellan Stem Cells for Therapy Development

Charles River Laboratories and Magellan Stem Cells announce their collaboration to support Magellan in the development and clinical advancement of its proprietary stem cell-based therapies and regenerative medicine solutions. The partnership will leverage Charles River's specialized expertise in biologics quality control, current Good Manufacturing Practice viral and release testing, and extensive development support services.

Charles River Laboratories and Autolomous Launch Apollo Orchestrate

Charles River Laboratories International and Autolomous announced the launch of Apollo Orchestrate, a new capability within Charles River's Apollo platform that connects and digitizes laboratory execution, built on Autolomous's autoloMATE digital Laboratory Execution System. Apollo Orchestrate marks a significant milestone in the Company's broader, ongoing transition toward a fully digital laboratory experience which is connected, compliant, and scalable. "Biological testing ensures that a medicine is safe, effective, and ready for patients, but data collection and management across fragmented, often manual and paper-based systems from R&D to commercial release create unnecessary delays for patients, opportunities for errors, audit risks, and lost revenue," said Alexander Seyf, CEO of Autolomous. "We designed autoloMATE to enable life sciences companies to connect that data directly into an integrated, digitized workflow and increase speed, accuracy, and cost-effectiveness."

PMGC Holdings Subsidiary Signs Statement of Work with Charles River Laboratories

PMGC Holdings (PMGC) announced that its subsidiary, NorthStrive Biosciences has executed a Statement of Work with Charles River Laboratories (CRL) to conduct analytical characterization supporting the development of NorthStrive Biosciences' EL-22 and EL-32 engineered probiotic programs. Under the SOW, Charles River will perform specialized analytical testing designed to characterize plasmid copy numbers in NorthStrive's engineered bacterial product candidates.